Business Zenas BioPharma Showcases Obexelimab Success, Plans BLA Filing Zenas BioPharma (NASDAQ: ZBIO) has announced significant progress with its investigational drug, obexelimab, during a presentation at the Guggenheim Emerging Outlook Biotech Summit 2026.... Editorial14 hours ago